2[1]Emst E, Resch KL. Fibrinogen as a Cardiovascular risk factor: A meta- analysis and review of the literature [ J] . Ann Intern med,1993, 118:956 - 963.
3[2]Becker RC , Cannon CP , Bovill EG , et al . Prognostic Value of plasma fibrinogen concentration in patients with unstable angina and non - Q - wave myocardial infarction [ J]. Am J Cardiol , 1996,78:142 - 147.
4Gersh BJ, Braunwald E, Rutherford JD. Chronic coronary artery disease. In : Braunwald E, editor. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: Saunders, 1997.1289 - 1365.
5Braunwald E, Antmml EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non - ST - segment elevation myocardial infarction. A report of the American College of Cardiodog/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable Angina). J Am Coil Cardiol, 2000, 36 ( 3 ) : 970.
6Yu H, Rifai N. High - sensitivity C - reactive protein mad atherosclerosis : from theory, to therapy. Clin - Biochem, 2000, 33 (8) : 601.
7Rifai N, Ridker PM. High - sensitivity C - reactive protein : a novel and promising marker of coronary heart disease. Clin - Chem, 2001,47(3) :403.
8PmmiUeri G,Marino B,Campa pp,et al.Interleukins 6 mad 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol, 1997,80(5) : 623.
9Rus H, Niculescu F1. Inflmnmation aspirin mad the risk of cardiovascular disease,N Engl J Meal, 1997,337(6) : 423.
10Abdelmouttaleb I, Dmachin N, Ilardo C, et at. C - reactive protein and coronary artery disease:Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J, 1999,137(2) : 346.
4Visser M, Bouter LM, Mcquillen GM, et al. Elevated C-reactive protein levels in overweight and obese adults[J]. JAMA, 1998, 282:2132-2135.
5Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C reactive protein and serum amyloid Aprotein in severe unsta ble angina[J]. N Engl J Med, 1994,331:417-424.
6Kantor PF, Lucien A,Kozak R,et al. The antianginal drug trime tazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitoehondrial long chain 3-ketoaeyl eoenzyme A thiolase[J]. Cite Res, 2000,86 (5) : 580-588.
7Kuralay F, Altekin E, Yazlar AS, et al. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine[J]. Tohoku J Exp Med,2006,208(3) :203-212.
8Williams FM, Tanda K, Kus M, et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits[J]. J Cardiovase Pharmacol, 1993,22 : 828-833.
9Tabbi Anneni I, Lueion A, Grynberg A. Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequences in alpha-adrenergic signaling [J]. Fumdamental&Clinical Pharma- cology,2003,17(1) :51-59.
10Bayram E, Atalay C,Koeaturk H,et al. Effects of trimetazidine on lipid peroxidation,antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale [J]. The Journal of International Research, 2005, 33 ( 6 ) : 612- 619.
